By Catherine Eckford2025-08-29T13:23:58
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-03T12:02:00Z
2026-06-01T08:21:00Z
Sponsored by Gilson
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
2025-12-11T13:32:00
Sponsored by Hexagon
Site powered by Webvision Cloud